INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study

Melissa Bersanelli, Paola Castrignanò, Stefano Panni, Francesca Mazzoni, Marcello Tiseo, Sabrina Rossetti, Elisabetta Gambale, Ernesto Rossi, Anselmo Papa, Alessio Cortellini, Maria Michiara, Emmanuele De Luca, Mariella Sorarù, Claudia Mucciarini, Francesco Atzori, Giuseppe L. Banna, Leonardo La Torre, Maria G. Vitale, Francesco Massari, Sara E. RebuzziGaetano Facchini, Giovanni Schinzari, Silverio Tomao, Simona Bui, Vanja Vaccaro, Matteo Santoni, Corrado Ficorella, Roberto Sabbatini, Antonio Maestri, Clara Natoli, Michele De Tursi, Elena Rapacchi, Annagrazia Pireddu, Teodoro Sava, Helga Lipari, Francesca Comito, Francesco Leonardi, Sebastiano Buti

Research output: Contribution to journalArticle

Abstract

Aim: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. Methods: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. Results: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23-4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77-31.14; p <0.0001. Conclusion: Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy.
Original languageEnglish
Pages (from-to)1229-1239
Number of pages11
JournalImmunotherapy
Volume10
Issue number14
DOIs
Publication statusPublished - Oct 1 2018

Keywords

  • immune checkpoint inhibitors, influenza syndrome, influenza vaccine

Fingerprint Dive into the research topics of 'INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study'. Together they form a unique fingerprint.

  • Cite this

    Bersanelli, M., Castrignanò, P., Panni, S., Mazzoni, F., Tiseo, M., Rossetti, S., Gambale, E., Rossi, E., Papa, A., Cortellini, A., Michiara, M., Luca, E. D., Sorarù, M., Mucciarini, C., Atzori, F., Banna, G. L., Torre, L. L., Vitale, M. G., Massari, F., ... Buti, S. (2018). INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study. Immunotherapy, 10(14), 1229-1239. https://doi.org/10.2217/imt-2018-0080